Patient Square Capital

Eargo, Inc. is a consumer-focused medical device company based in San Jose, California, that specializes in developing and selling innovative hearing aids for individuals experiencing hearing loss. Founded in 2010, Eargo offers a range of rechargeable hearing aids that can be controlled via smartphone, addressing common barriers to hearing aid adoption such as cost, accessibility, and social stigma. The company provides online hearing screenings and virtual support, allowing customers to receive assistance without needing in-person visits. Eargo's products are available for purchase online or over the phone, and the company emphasizes personalized consultations with licensed hearing professionals through various communication channels. By offering its solutions at approximately half the cost of traditional hearing aids, Eargo aims to enhance the quality of life for people with hearing impairments.

Alladapt Immunotherapeutics, Inc. is a biopharmaceutical company focused on developing therapeutics for food allergies. Founded in 2018 and based in Menlo Park, California, the company is advancing its lead program, ADP101, which aims to provide a broad-spectrum oral immunotherapy treatment. This innovative drug targets the mitigation, treatment, and prevention of food allergies caused by single or multiple proteins from a wide range of common allergens. Through its research and development efforts, Alladapt Immunotherapeutics seeks to enable healthcare providers to effectively address the challenges faced by patients with various food allergies.

Kriya Therapeutics, Inc. is a gene therapy company based in Palo Alto, California, with an additional office in Durham, North Carolina. Founded in 2019, the company specializes in designing and developing innovative treatments for chronic diseases that are both prevalent and severe. Kriya Therapeutics focuses on conditions with well-understood underlying biology, aiming to create one-time gene therapies that provide durable expression of therapeutic proteins in targeted human tissues. The company's team comprises experts and former leaders from prominent gene therapy firms and academic institutions. Utilizing algorithmic tools, scalable infrastructure, and proprietary technology, Kriya Therapeutics seeks to enhance the efficacy and longevity of its therapies, striving to redefine treatment approaches for serious health conditions.

Enavate Sciences is a private equity firm established in 2022 and located in New York, New York. The firm focuses on investing in and fostering the strategic growth of innovative companies within the therapeutic and enabling technology sectors of life sciences. Enavate Sciences targets both pre-clinical and clinical-stage organizations, aiming to support their development and commercialization efforts. By concentrating on these areas, the firm seeks to advance healthcare solutions and contribute to the evolution of the life sciences industry.

Roivant Sciences is a commercial-stage biopharmaceutical company focused on enhancing healthcare delivery through innovative drug development. The company aims to reduce the time and cost associated with bringing new medicines to market, sharing those savings with the healthcare system. Roivant achieves this by creating specialized entities known as Vants, which are agile biotech and healthcare technology firms that leverage unique talent sourcing and technology deployment strategies. In addition to its biopharmaceutical subsidiaries, Roivant incubates discovery-stage companies and health technology startups that complement its core business. Among its drug candidates, VTAMA (tapinarof) is designed for the treatment of plaque psoriasis and has reached the commercial stage, while several other candidates, including Batoclimab, IMVT-1402, Brepocitinib, and Namilumab, are in various stages of development.

Kriya Therapeutics, Inc. is a gene therapy company based in Palo Alto, California, with an additional office in Durham, North Carolina. Founded in 2019, the company specializes in designing and developing innovative treatments for chronic diseases that are both prevalent and severe. Kriya Therapeutics focuses on conditions with well-understood underlying biology, aiming to create one-time gene therapies that provide durable expression of therapeutic proteins in targeted human tissues. The company's team comprises experts and former leaders from prominent gene therapy firms and academic institutions. Utilizing algorithmic tools, scalable infrastructure, and proprietary technology, Kriya Therapeutics seeks to enhance the efficacy and longevity of its therapies, striving to redefine treatment approaches for serious health conditions.

Apollo Therapeutics is a collaborative initiative involving three prominent UK universities—Imperial College London, University College London, and the University of Cambridge—and three major pharmaceutical companies: AstraZeneca, GlaxoSmithKline, and Johnson & Johnson Innovation. The organization focuses on funding and developing novel therapeutics derived from leading British academic research, facilitating their progression toward clinical application. With a model that provides rapid access to resources, Apollo Therapeutics champions innovative research and enhances collaboration between academia and industry. Its team of experienced scientists, who have a strong track record in therapeutic delivery, works closely with academic researchers and industry partners to tailor projects for optimal success. The overarching goal of Apollo Therapeutics is to advance future therapies that significantly improve patient treatments and outcomes.